Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Details

Ressource 1Download: serval:BIB_7BC299FDB2D0.P001 (286.30 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_7BC299FDB2D0
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).
Journal
Graefe's Archive for Clinical and Experimental Ophthalmology
Author(s)
Konstantinidis L., Mameletzi E., Mantel I., Pournaras J.A., Zografos L., Ambresin A.
ISSN
1435-702X[electronic]
Publication state
Published
Issued date
2009
Peer-reviewed
Oui
Volume
247
Number
9
Pages
1165-1171
Language
english
Abstract
BACKGROUND: Retinal angiomatous proliferation (RAP) is a distinct variant of neovascular age-related macular degeneration (AMD). The aim of this study is to evaluate the functional and anatomic outcome after intravitreal ranibizumab (Lucentis) treatment in patients with RAP. METHODS: Prospective study of consecutive patients with newly diagnosed or recurrent RAP treated with intravitreal ranibizumab at the Jules Gonin Eye Hospital between March 2006 and December 2007. Baseline and monthly follow-up visits included best-corrected visual acuity (BCVA), fundus exam and optical coherence tomography. Fluorescein and indocyanine green angiography were performed at baseline and repeated at least every 3 months. RESULTS: Thirty-one eyes of 31 patients were treated with 0.5 mg of intravitreal ranibizumab for RAP between March 2006 and December 2007. The mean age of the patients was 82.6 years (SD:4.9). The mean number of intravitreal injections administered for each patient was 5 (SD: 2.4, range 3 to 12). The mean follow up was 13.4 months (SD: 3, range 10 to 22). The baseline mean logMAR BCVA was 0.72 (SD: 0.45) (decimal equivalent of 0.2). The mean logMAR BCVA was improved significantly (P < 0.0001) at the last follow-up to 0.45, SD: 0.3 (decimal equivalent 0.35). The visual acuity (VA) improved by a mean of 2.7 lines (SD 2.5). Mean baseline central macular thickness (CMT) was 376 microm, and decreased significantly to a mean of 224 microm (P < 0.001) at the last follow-up. Mean reduction of CMT was 152 microm (SD: 58). An average of 81.5% of the total visual improvement and 85% of the total CMT reduction occurred during the first post-operative month after one intravitreal injection of ranibizumab. During follow-up, an RPE tear occurred in one eye (3.2%) of the study group. No injection complications or systemic drug-related side-effects were noted during the follow-up period. CONCLUSIONS: Intravitreal ranibizumab injections appeared to be an effective and safe treatment for RAP, resulting in visual gain and reduction in macular thickness. Further long-term studies to evaluate the efficacy of intravitreal ranibizumab in RAP are warranted.
Keywords
Aged, Aged, 80 and over, Angiogenesis Inhibitors/adverse effects, Angiogenesis Inhibitors/therapeutic use, Angiomatosis/drug therapy, Angiomatosis/physiopathology, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal/therapeutic use, Coloring Agents/diagnostic use, Female, Fluorescein Angiography, Follow-Up Studies, Humans, Indocyanine Green/diagnostic use, Injections, Macular Degeneration/drug therapy, Macular Degeneration/physiopathology, Male, Retinal Diseases/drug therapy, Retinal Diseases/physiopathology, Retrospective Studies, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A/antagonists &amp, inhibitors, Visual Acuity/physiology, Vitreous Body
Pubmed
Web of science
Open Access
Yes
Create date
29/09/2009 14:24
Last modification date
01/10/2019 6:18
Usage data